Overview
Maroteaux-Lamy syndrome, also known as Mucopolysaccharidosis Type VI (MPS VI), is a rare autosomal recessive lysosomal storage disorder caused by a deficiency in the enzyme arylsulfatase B (ARSB). This deficiency leads to the accumulation of dermatan sulfate in various tissues, resulting in multisystem involvement including skeletal, cardiovascular, and neurological manifestations. Clinical presentation typically emerges in early childhood, with progressive symptoms affecting quality of life and longevity. Management strategies aim to mitigate symptoms and improve functional outcomes through a combination of supportive care, surgical interventions, and, where applicable, enzyme replacement therapy (ERT). Understanding the pathophysiology and recognizing early clinical signs are crucial for timely intervention and improved prognosis.
Pathophysiology
The core pathophysiological defect in Maroteaux-Lamy syndrome lies in the impaired degradation of dermatan sulfate due to ARSB deficiency. This accumulation leads to cellular dysfunction and tissue damage across multiple systems. Notably, one of the significant manifestations involves the spinal column, where hypertrophy of the ligamentum flavum is frequently observed [PMID:15823680]. This hypertrophy contributes substantially to spinal cord compression, often affecting multiple levels from cervical to lumbar regions. The resultant cord compression can lead to progressive neurological deficits, emphasizing the importance of early imaging and monitoring spinal changes. Additionally, the cardiovascular system is frequently affected, with echocardiographic findings often revealing thickened and fibrotic aortic and mitral valves, indicative of valvular stenosis [PMID:1728449]. These cardiovascular complications underscore the systemic nature of the disease and the need for comprehensive multidisciplinary care.
Clinical Presentation
Clinical manifestations of Maroteaux-Lamy syndrome are diverse and can vary widely among patients, reflecting the multisystem involvement characteristic of lysosomal storage disorders. Neurological symptoms are prominent and often include developmental delays, motor dysfunction, and cognitive impairment. An illustrative case involved an 18-year-old male presenting with spastic quadriparesis, highlighting the severity of neurological deficits that can arise [PMID:15823680]. This presentation is consistent with the progressive nature of spinal cord compression due to ligamentum flavum hypertrophy. Beyond neurological symptoms, patients frequently exhibit skeletal abnormalities such as short stature, joint stiffness, and dysostosis multiplex. Cardiovascular involvement is another critical aspect, with thickened and fibrotic aortic and mitral valves often detected via echocardiography, potentially leading to heart failure or valvular insufficiency [PMID:1728449]. These varied presentations necessitate a thorough clinical evaluation to identify and address multiple organ systems affected by the disease.
Diagnosis
Diagnosing Maroteaux-Lamy syndrome involves a combination of clinical evaluation, biochemical testing, and genetic analysis. Initial suspicion often arises from characteristic clinical features, but definitive diagnosis relies on confirming ARSB deficiency. Traditional methods such as measuring ARSB activity in leukocytes or fibroblasts are standard, but advancements in genetic testing have expanded diagnostic capabilities. For instance, complete sequencing of the coding regions of ARSB may not always identify pathogenic variants, as seen in cases where deep sequencing of noncoding regions via whole genome sequencing revealed pathogenic intronic variants [PMID:34435740]. This highlights the importance of employing comprehensive genetic approaches, including whole exome or genome sequencing, to uncover hidden mutations. Imaging studies, particularly magnetic resonance imaging (MRI), play a crucial role in assessing spinal involvement, often revealing stenosis at multiple levels of the cervical, thoracic, and lumbar regions [PMID:15823680]. These imaging findings are essential for planning surgical interventions aimed at decompressing affected spinal levels.
Differential Diagnosis
Differentiating Maroteaux-Lamy syndrome from other lysosomal storage disorders and non-genetic conditions can be challenging due to overlapping clinical features. Conditions such as other types of mucopolysaccharidoses (MPS), skeletal dysplasias, and certain neuromuscular disorders may present with similar symptoms, particularly in terms of skeletal deformities and neurological deficits. The presence of specific cardiovascular manifestations, like valvular stenosis, can help narrow the differential but requires careful clinical correlation. Preoperative assessment in these patients is further complicated by the potential presence of other malformations, which can complicate airway management and surgical planning [PMID:1728449]. Therefore, a multidisciplinary approach involving geneticists, cardiologists, neurologists, and orthopedic specialists is crucial for accurate diagnosis and comprehensive management planning.
Management
The management of Maroteaux-Lamy syndrome is multifaceted, tailored to address the diverse manifestations of the disease. Enzyme replacement therapy (ERT) with recombinant human ARSB has emerged as a cornerstone treatment when available, aiming to reduce substrate accumulation and alleviate symptoms. Identification of the genetic cause through advanced sequencing techniques, such as whole genome sequencing, not only aids in diagnosis but also enables targeted ERT, as demonstrated in cases where deep intronic variants were identified [PMID:34435740]. Beyond pharmacological interventions, surgical management plays a pivotal role, particularly for spinal cord compression. Patients often require staged decompressive surgeries targeting multiple levels of the spine, guided by comprehensive imaging evaluations [PMID:15823680]. For cardiovascular complications, surgical interventions such as valve replacement may be necessary, as evidenced by successful double-valve replacements in affected siblings [PMID:1728449]. Supportive care, including physical therapy, orthopedic interventions, and management of respiratory complications, is also integral to improving quality of life and functional outcomes.
Complications
Despite advances in diagnosis and treatment, patients with Maroteaux-Lamy syndrome face significant complications that can impact prognosis and overall health. Postoperative complications are particularly concerning, with reports of severe infections such as septicemia following surgical interventions, as seen in the case of a sibling who succumbed to septicemia post-hip surgery [PMID:1728449]. These complications highlight the need for stringent perioperative care, including meticulous infection control measures and close monitoring post-surgery. Additionally, progressive neurological decline due to untreated or inadequately managed spinal cord compression can lead to irreversible motor deficits and cognitive impairment. Cardiovascular complications, including heart failure secondary to valvular disease, further complicate the clinical picture, necessitating vigilant monitoring and timely intervention to mitigate these risks.
Prognosis & Follow-up
The prognosis for individuals with Maroteaux-Lamy syndrome varies widely depending on the severity of organ involvement and the timeliness and effectiveness of interventions. While some patients benefit significantly from early diagnosis and comprehensive management, including ERT and surgical decompression, others may experience rapid disease progression leading to severe disability or premature mortality. The variability underscores the importance of individualized assessment and tailored treatment plans. Follow-up care should be multidisciplinary, involving regular evaluations by neurologists, cardiologists, orthopedic specialists, and geneticists to monitor disease progression and manage emerging complications. Imaging studies, particularly MRI, should be conducted periodically to assess spinal changes and guide surgical interventions as needed. Despite successful interventions, the potential for severe complications such as septicemia emphasizes the necessity for vigilant postoperative care and long-term monitoring to optimize outcomes and quality of life.
Key Recommendations
References
1 Marek-Yagel D, Eliyahu A, Veber A, Shalva N, Philosoph AM, Barel O et al.. Deep intronic variant in the ARSB gene as the genetic cause for Maroteaux-Lamy syndrome (MPS VI). American journal of medical genetics. Part A 2021. link 2 Mut M, Cila A, Varli K, Akalan N. Multilevel myelopathy in Maroteaux-Lamy syndrome and review of the literature. Clinical neurology and neurosurgery 2005. link 3 Tan CT, Schaff HV, Miller FA, Edwards WD, Karnes PS. Valvular heart disease in four patients with Maroteaux-Lamy syndrome. Circulation 1992. link